05/03/2026
World Obesity Day is a reminder that behind every statistic is a life shaped by biology, environment, and circumstance, that obesity is not a matter of willpower, but a chronic, relapsing disease requiring sustained, science-based solutions. This year's theme—“8 Billion Reasons to Act”—reflects the scale of the challenge: in 2015, high BMI was associated with 4 million deaths globally, driven by cardiovascular disease, diabetes, chronic kidney disease, and cancer. Obesity is a chronic, relapsing disease, and more than 80% of people living with obesity develop related health complications. One of the most common is fatty liver disease, which often has no obvious symptoms but can improve or even be reversed with evidence-based weight management.
The trajectory often begins early. In China, the combined rate of overweight and obesity among children aged 7-18 has risen from 1.2% in 1985 to 23.4% in 2019, underscoring an urgent and persistent unmet need. Globally, nearly half of the world's population is projected to be living with overweight or obesity by 2035, making prevention, early intervention, and equitable access to care more urgent than ever.
Addressing obesity and its cardiometabolic consequences aligns closely with Innovent's broader mission to expand access to high-quality biologics and treatment support for patients facing serious unmet medical needs, including through our cardiovascular and metabolic disease research efforts. On this World Obesity Day, we stand with the global health community in advancing understanding over stigma, science over simplification, and supporting evidence-based care that can change long-term outcomes.
